Below The Knee | Market Signal

CAMP Bifurcation Accelerates: Autologous Winners Pull Away From Reimbursement-Compressed Pure Plays

The week made one thing crystal clear. CAMP doesn't have a reimbursement problem. CAMP has a composition problem.

APWCA this week sounded a loud alarm on CY2027 Medicare ASP data: distressed inventory clearance from manufacturers facing compliance pressure could artificially depress baselines for sheet-form CAMP allografts, triggering downward reimbursement feedback loops. Current $127.14/cm² rate is already under fire on Capitol Hill. A recalibrated rate tethered to fire-sale ASP from 2026 is an existential risk for CAMP-pure plays.

But here's the move nobody's talking about. While CAMP-pure players face margin compression, the winners pivoting away from allograft dependency are gaining traction. AVITA raised full-year 2026 guidance on PermeaDerm RCT results showing 70% cost advantage over allograft and 96% reduction in prep time. Nuo reported 150%+ YoY revenue growth on Aurix, its autologous PRP hematogel. BioStem pivoted hard away from perinatal allografts into hospital-focused DRG reimbursement for regenerative procedures, posting 29% sequential Q2 growth to $7.9M and repositioning 87% of revenue into procedure-based reimbursement that doesn't depend on CMS sheet-form pricing.

BioLab's acquisition of FastSkin, an autologous wound care platform, is the consolidation story that proves it. Smaller players carrying concentrated CAMP exposure are being scooped up by platforms betting on autologous, cellular, and hospital-DRG models as the durable reimbursement narrative.

Meanwhile, vascular intervention is having a real week. Humacyte cleared FDA IND for first-in-human CTEV/CABG trials—cardiac expansion for a regenerative vascular player. Vesalio got 510(k) clearance for pVasc NET peripheral thrombectomy device. And MolecuLight published evidence that bacterial imaging predicts CAMP outcomes, a clinical insight that could become the standard diagnostic before CAMP application, fundamentally shifting clinical workflow.

One category. Three trajectories. CAMP-pure compression, autologous/cellular traction, vascular expansion. Choose your narrative.

Here's the week.

Upcoming: Wounds Australia is three days away (Adelaide, Aug 23–26). IPAWS & Tissue Repair Summit (New Orleans, Ritz-Carlton) is in 24 days, and BTK is your Official Market Intelligence Partner. Fall conference season is open. Intelligence platform tracking all major events through Q4.

Reimbursement | APWCA Warns CY2027 Medicare Physician Fee Schedule CAMP ASP Risk; Distressed Pricing Could Trigger Downward Feedback Loop

The American Professional Wound Care Association submitted public comments to CMS urging stakeholders to submit input on the CY2027 Medicare Physician Fee Schedule rule-making by September 14 deadline. APWCA's core concern: 2026 average sales price (ASP) data for CAMPs may reflect distressed inventory clearance from manufacturers managing compliance and reimbursement pressure, not normalized commercial pricing. If heavily discounted 2026 ASP becomes the baseline for CY2027 reimbursement, sheet-form CAMP rate could compress further from current $127.14/cm², creating a downward feedback loop that hits viability for smaller-cap pure plays.

The BTK read: This is the structural reimbursement risk that's moving the needle on CAMP-pure player multiples. ASP distortion from inventory clearance is the technical mechanism for pricing compression. Manufacturers know it. Payers know it. Clinicians know it. The result is bifurcation: players that diversified away from CAMP exposure are executing growth plans; CAMP-pure plays are facing margin pressure and consolidation risk. Current $127.14/cm² is not a floor. It's a question mark.

Regulatory | FDA Explores "Competency-Based" AI Medical Device Evaluation Framework

The FDA is developing a new evaluation approach for generative AI-enabled medical devices, benchmarking performance against qualified clinicians and assessing real-world clinical performance. The framework recognizes that AI devices evolve and produce variable outputs, shifting emphasis toward post-market monitoring and continuous performance assessment rather than static pre-market clearance models.

The BTK read: This is structural change for AI-driven diagnostics in wound care. MolecuLight's bacterial imaging technology, point-of-care wound analysis platforms, and AI-assisted reimbursement coding systems now have regulatory clarity. Competency-based benchmarking against clinicians is the standard for medtech. Watch for how this accelerates adoption of AI diagnostics in wound centers and hospital systems facing compliance scrutiny.

Clinical | MolecuLight Publishes Research Showing Bacterial Imaging Predicts CAMP Success and Improves Wound Bed Readiness

MolecuLight presented newly published research demonstrating that its fluorescence imaging technology can predict success of cellular and acellular matrix products (CAMPs) and improve wound bed preparation prior to application. The findings highlight that CAMP failure is often tied to bacterial burden and suboptimal wound bed readiness—areas where point-of-care fluorescence imaging provides actionable, real-time guidance. Research reinforces MolecuLight's value proposition in skin substitutes, where payers and clinicians increasingly scrutinize appropriate use and outcomes.

The BTK read: This is the diagnostic-guided CAMP workflow story. If bacterial imaging becomes standard pre-CAMP assessment, it changes application rates and success rates simultaneously. Payers will want outcome data linking pre-application imaging to CAMP success rates. Manufacturers should be tracking MolecuLight adoption trends in their key accounts—this could become a competitive hygiene factor. Also note: imaging-guided CAMP application improves outcomes and potentially reduces unnecessary applications, addressing payer concerns about CAMP overutilization.

Market | AVITA Medical Raises 2026 Guidance After PermeaDerm RCT Shows 70% Cost Advantage Over Allograft

AVITA Medical announced positive multicenter randomized controlled trial results for PermeaDerm, its biosynthetic wound matrix, demonstrating 70% economic advantage over allograft on a per-percent-total-body-surface-area basis, with comparable clinical outcomes for graft take, wound healing, and safety. PermeaDerm also achieved 96% reduction in preparation time and eliminated logistical burdens of allograft thawing and tissue tracking. On the strength of these results and Q2 sales growth of 18% year-over-year, AVITA raised full-year 2026 revenue guidance, signaling confidence in autologous and biosynthetic skin substitute adoption.

The BTK read: PermeaDerm's 70% cost advantage over allograft is the payer narrative that moves adoption. Cost-plus clinical parity is the winning CAMP positioning. AVITA's guidance raise reflects strong execution on surgical burn and soft-tissue reconstruction—markets where CAMP choice is clinical and financial. This is how winners compete: superior economics plus clinical data. Contrast against allograft pure plays facing margin compression from ASP distortion.

Market | BioStem Technologies Pivots Away From Wound Care CAMP Exposure; Targets Hospital-Focused DRG Reimbursement

BioStem Technologies is repositioning from wound-care business exposed to CMS CAMP pricing pressure toward a surgical, hospital-focused regenerative medicine platform, with 87% of current revenue now tied to procedure-based DRG reimbursement. Q2 2026 revenue reached $7.9M, up 29% sequentially, with commercial expansion into urology, foot & ankle, orthopedics, and spine. The company is targeting improved margins through planned in-house manufacturing, reducing reliance on third-party reimbursement volatility.

The BTK read: BioStem's strategic pivot is the early-stage version of what mature CAMP players should be doing. Move revenue out of sheet-form CAMP ASP exposure into procedure-based DRG reimbursement where price certainty is built into hospital payment models. 87% of revenue now in DRG-based procedures means BioStem is largely insulated from CAMP reimbursement compression. This is portfolio engineering in real time, and it's working. Watch other perinatal-derived product companies—this is the playbook.

Market | BioLab Holdings Acquires FastSkin Autologous Wound Care Technology

BioLab Holdings has added FastSkin, an autologous wound care technology utilizing patient-derived biological material, to its tissue restoration portfolio. The acquisition signals continuing consolidation in the advanced wound care space and growing market appetite for autologous alternatives to donor-derived and synthetic skin substitutes amid evolving CMS reimbursement scrutiny.

The BTK read: FastSkin acquisition is the portfolio insurance move. BioLab is building out autologous and cellular capabilities as alternatives to traditional allograft exposure. Smaller-cap CAMP-pure players with unique autologous platforms are seeing M&A interest as larger tissue restoration platforms hedge against CAMP reimbursement compression. Worth tracking for BioLab's commercial integration strategy and whether FastSkin becomes a platform anchor for autologous expansion.

Market | Nuo Therapeutics Reports Q2 2026 Revenue Surge 150%+ YoY; Aurix Autologous PRP Platform Drives Growth

Nuo Therapeutics reported Q2 2026 total revenues of approximately $1.77M, up in excess of 150% versus Q2 2025, with product revenue increasing 38% sequentially versus Q1 2026 and Aurix autologous PRP hematogel revenues increasing more than 30% sequentially. Q2 operating loss improved approximately $280K compared to Q1, signaling improved unit economics as the company scales Aurix commercialization in chronic wound care.

The BTK read: Nuo's 150%+ YoY revenue growth is the autologous traction story. Aurix is a point-of-care, patient-derived biologic—no allograft ASP exposure, no complex supply chain, no reimbursement bifurcation risk. Sequential growth acceleration into Q2 suggests clinical adoption is driving volume expansion. Operating loss improvement on rapidly scaling revenue means Nuo is approaching profitability trajectory. This is how autologous platforms compete: speed of adoption + favorable unit economics + clinical simplicity.

Market | Coloplast Reports Q3 Organic Growth 6%; Wound & Tissue Repair Segment Grows 3% Organically

Coloplast reported third-quarter organic growth of 6% with 5% EBIT growth in constant currencies. Wound & Tissue Repair segment grew 3% organically, reflecting steady but modest demand in advanced wound care. Chronic Care (excluding China) and Interventional Urology drove stronger performance, while Biologics segment faced continued reimbursement-related headwinds.

The BTK read: Coloplast's Wound & Tissue Repair 3% growth is the large-cap in-line story. No acceleration, no deceleration. Steady performance in a category facing pricing pressure suggests Coloplast's scale and payer relationships are keeping volumes stable even as margins compress. Biologics headwinds are worth tracking—that segment is where CAMP and advanced wound care compete, and reimbursement pressure is real.

Market | Coloplast Announces Executive Leadership Team Changes

Coloplast announced modifications to its Executive Leadership Team, signaling potential strategic shifts for the Danish medtech company. Leadership changes at this scale often precede portfolio reviews, reimbursement strategy recalibrations, or commercial reorganization in response to category dynamics.

The BTK read: Executive churn at Coloplast should be monitored against their Wound & Tissue Repair strategy. Large-cap medtech leadership changes in regulated businesses are typically orchestrated around strategic pivots. Coloplast's Biologics headwinds could be prompting questions about portfolio mix and reimbursement strategy. Watch for updated commentary on wound care strategy and pricing policy in next earnings call.

Market | OMEZA Appoints Chief Commercial Officer to Accelerate Advanced Wound Care Growth

OMEZA has hired a new Chief Commercial Officer with decades of advanced wound care commercial experience to lead market expansion. The appointment signals intent to scale sales presence and competitive positioning in the wound care segment, typically preceding accelerated account targeting, territory expansion, or preparation for fundraising or partnership announcement.

The BTK read: CCO hire is the commercial acceleration signal. OMEZA is repositioning for growth. Watch for whether new commercial leadership is tied to R&D advances, reimbursement clarity for existing products, or preparation for a fundraising event. Leadership hires at this level don't happen without capital commitment.

Regulatory | Vesalio Receives FDA 510(k) Clearance for pVasc NET Peripheral Thrombectomy Device

Vesalio announced FDA 510(k) clearance for pVasc NET, a next-generation peripheral mechanical thrombectomy device with integrated distal filter for treatment of thromboembolic disease in peripheral vasculature. The clearance expands Vesalio's pVasc platform for minimally invasive removal of emboli and thrombi from peripheral vessels, supporting vascular intervention and limb salvage procedures in diabetic and non-diabetic patients with peripheral vascular disease.

The BTK read: pVasc NET clearance is the limb salvage toolkit expansion story. Thrombectomy capability integrated with distal protection is a high-value procedural tool for interventionalists managing acute ischemia in at-risk limbs. Vesalio's pVasc platform is building out modular capability. Track for adoption in PAD programs and whether this becomes a competitive differentiation point versus Penumbra and other thrombectomy platforms.

Clinical | Humacyte Misses Q2 Estimates But Advances CTEV/CABG Pipeline; FDA Accepts IND for First-In-Human Cardiac Repair Study

Humacyte reported Q2 2026 earnings miss (EPS −$0.16 vs. −$0.10 estimates; revenue $410K vs. $1.1M estimates), but the clinical news overshadowed near-term financial misses. The FDA accepted the company's IND application for a first-in-human coronary tissue-engineered vessel (CTEV) study in coronary artery bypass grafting (CABG), representing a major pipeline expansion for the regenerative vascular company. Symvess commercial sales reached $0.4M in Q2.

The BTK read: Humacyte's CTEV/CABG expansion is the strategic pivot story. Bioengineered vessels in cardiac repair represent a massive addressable market beyond peripheral vascular and dialysis access. This is the innovation pipeline validation. Near-term revenue miss is noise against the backdrop of first-in-human cardiac trial approval. Watch for trial enrollment trajectory and safety/efficacy data as the story unfolds. This could redefine Humacyte's market narrative from niche regenerative company to cardiac device innovator.

Market | Merit Medical Names Sheri Lewis Executive VP Global Operations

Merit Medical Systems appointed Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026, bringing 30 years of global operations and manufacturing experience from Medtronic and Avantor. The leadership change supports Merit's vascular intervention and medical device portfolio amid ongoing tariff pressures and operational optimization priorities.

The BTK read: COO hire from Medtronic is the operational discipline play. Merit Medical is a vascular intervention and medical device platform facing tariff headwinds and scale-up challenges. Bringing in a 30-year Medtronic operator signals focus on manufacturing efficiency, supply chain optimization, and margin protection in a tariff-constrained environment. This is defensive portfolio management.

Market | Smith & Nephew Finance Chief John Rogers Abruptly Resigns; Board Departure Creates Leadership Uncertainty

Smith & Nephew's finance chief John Rogers has abruptly resigned from the board and will depart next month, following controversy over a new pay policy for US-based executives. The sudden CFO departure creates leadership uncertainty at one of the world's largest wound care and orthopedic medtech companies and could affect investor confidence and strategic execution across S&N's wound management and vascular portfolios.

The BTK read: S&N CFO resignation is the leadership disruption story. Finance chiefs don't resign abruptly over compensation disputes without deeper organizational dysfunction. This signals potential internal conflict on strategic direction, capital allocation, or international reimbursement strategy. S&N's wound care and vascular portfolios are central to BTK markets. Watch for updated guidance, portfolio commentary, or strategic announcements in next earnings call. Leadership uncertainty at scale typically precedes portfolio moves.

Market | NEXGEL Pulls SilverSeal From Amazon; Shifts to Higher-Margin Hospital Channel

NEXGEL strategically recalled its entire SilverSeal wound-care inventory from Amazon, incurring ~$144K in Q2 expense, to reposition the product for hospital-market launch beginning August 2025. SilverSeal holds reimbursement A-codes enabling coverage across hospitals, ASCs, and physician offices, expected to drive higher gross margins than consumer e-commerce. Q2 revenue reached $3.69M with net loss ~$2.87M. The move is part of broader NEXGEL transformation following Celularity acquisition and BioNX Surgical division buildout.

The BTK read: NEXGEL's Amazon-to-hospital pivot is the reimbursement-driven channel strategy story. A-code coverage makes hospital procurement significantly higher-margin than consumer e-commerce. Pulling $144K in inventory suggests disciplined portfolio management and confidence in hospital adoption. Watch for how quickly SilverSeal gains hospital traction and whether margin improvement accelerates as hospital mix increases. This is channel optimization executing against payer reimbursement clarity.

Market | Wound Management Specialists Files Chapter 11; $100M–$500M Liability Overhang Signals Advanced Wound Care Services Distress

Wound Management Specialists, LLC, a Flowood, MS-based advanced wound care services provider, filed for Chapter 11 bankruptcy on August 18, 2026 in the Southern District of Mississippi, reporting $10M–$50M in assets against $100M–$500M in liabilities. The severe liability overhang signals significant financial distress within the wound care services sector and could impact supplier relationships, payer contracts, and patient continuity of care.

The BTK read: WMS bankruptcy is the services sector stress story. Concentrated wound care services providers carrying large liability burdens (likely Medicare recoupments, CCPA settlements, or malpractice exposure) are facing cash flow crises. This is a canary in the coal mine for other wound care centers and service providers. Watch for supplier impacts and whether other service-heavy operators are facing similar pressure. Payer audits of wound care billing are accelerating, and providers are feeling it.

Market | Applied Biologics Launches National Health System Partnership Initiative; Expands Hospital Access and Clinical Education

Applied Biologics is expanding its commercial strategy with a new initiative targeting hospitals, IDNs, GPOs, ASCs, and wound care centers to strengthen adoption and access to XWRAP. The program combines expanded health-system engagement with clinical education, evidence generation, supply reliability, and dedicated resources for healthcare executives and clinical decision-makers.

The BTK read: Applied Biologics' health-system partnership program is the clinical adoption acceleration play. Structured programs targeting hospital executives and GPO buyers are the commercial blocking-and-tackling in advanced wound care. XWRAP's clinical evidence base and payer positioning will determine uptake velocity. This is mid-market execution against larger platforms.

Capital | Smith+Nephew and Imperial College London Launch Centre for Robotic Surgery Innovation

Smith+Nephew and Imperial College London have established a five-year partnership to accelerate innovation in musculoskeletal robotic surgery. The centre will embed Smith+Nephew engineers within Imperial's surgical robotics laboratory to translate academic breakthroughs in computer vision and sensing into advanced, less-invasive surgical techniques.

The BTK read: S&N's Imperial College partnership is the R&D innovation play. Strategic academic partnerships allow large medtech platforms to access cutting-edge robotics and surgical technique research without building from scratch. This signals S&N's continued focus on surgical innovation beyond traditional wound care and orthopedic implants. Robotic-assisted foot and ankle and lower limb reconstruction could be downstream adjacencies. Watch for commercialization timeline and product development outcomes.

BTK Wound Care Fund (5D): +0.005% | S&P 500: −1.86% | Dow Jones: −1.81% | NASDAQ: −2.48%

Fund advantage this week: +1.86% to +2.48% vs. broader indices

Top 5, five days:

Bottom 5, five days:

The BTK read: Complete week-over-week reversal. AVITA +28.54% on PermeaDerm RCT guidance raise is the headline—cost advantage over allograft and faster prep time move the needle on payer interest. BioStem +14.64% reflects market recognition of DRG pivot strategy; moving revenue away from CAMP ASP exposure is winning. Celularity +10.20% suggests biosynthetics and autologous exposure is in favor. Sensei and Sonoma both recovering week-on-week, indicating CAMP pure plays are finding footing after earlier enforcement pressures. Integra's sharp −9.54% reversal is worth watching—one week outperformer, this week underperformer. Boston Scientific down 4.75% on broader market headwinds despite Penumbra acquisition narrative. Fund outperformance vs. indices reflects portfolio diversification away from pure-play CAMP exposure and positioning in autologous/cellular winners.

Educational model portfolio. Not a real fund. Not investment advice. Performance is model-calculated and unaudited.

Coming Week:

August 23–26 | Adelaide, Australia — Wounds Australia 2026 — Adelaide Convention Centre

August 27–29 | Columbia, SC — Southeast Chapter of WOCN® Society Annual Conference — Columbia Metropolitan Convention Center

September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton (BTK Official Market Intelligence Partner)

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026 – World Union of Wound Healing Societies Congress — Kuala Lumpur Convention Centre

October 1–4 | Bengaluru, India — DFSICON 2026 — Hilton Garden Inn Bengaluru, Embassy Manyata Business Park

October 8–10 | New Delhi, India — ASVS–VSICON 2026 — Pullman & Novotel New Delhi Aerocity

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

See you next week,

-Scott